ClinicalTrials.gg
RecruitingNCT05451303Updated Jan 29, 2025

Detection of Oral and Throat Cancers Using OralViome Cancer Testing System

An observational study in Oral Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma and Premalignant Lesion, sponsored by Viome. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-29.

Sponsored by Viome · Observational

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
475
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 213 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Planned enrollment
14th of 62
475 · median 132
Started
2022
with 56 others
Observational
62 of 1,099
11 open now
Primary completion
2026-12
later than 83 of 346 live
Registered
840th of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 14th largest by planned enrollment of the 62 observational ones that give a count, is one of 57 that started in 2022, is one of 62 observational ones, reaches primary completion later than 83 of the 346 other live ones, and was the 840th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

213 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

208 more — sign in →

All 213 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

To evaluate the design, safety and efficacy of OralViome Cancer Testing system in the early detection of Oral and Throat Cancers using saliva metatranscriptomic analysis. This study will recruit only at existing clinical sites and will NOT use any additional clinical sites.

Read the detailed description

This is an observational study evaluating the design, safety and efficacy of OralViome Cancer Testing system in the early detection of Oral and Throat Cancers using saliva metatranscriptomic.

A total of 475 participants will be recruited, including 4 different cohorts: 1) cancer free patients, 2) patients with Oral Potentially Malignant Disease (OPMD), 3) patients with Oral Squamous Cell Carcinoma (OSCC), and 4) patients with OroPharyngeal Cancer (OPC). OSCC and OPC participants will be recruited from secondary care facilities, OPMD and cancer free participants will be recruited from primary care facilities.

Participants will complete health questionnaires and collect saliva samples using at home/ in clinic kits provided by Viome. The duration of study participation will be 1 clinic visit for cancer free participants, and up to 1 year for those with OSCC/OPC/OPMD.

03

Conditions studied

  • Oral Squamous Cell Carcinoma
  • Oropharynx Squamous Cell Carcinoma
  • Premalignant Lesion

Keywords

  • Viome
  • oral cancer
  • detection
  • OSCC
  • OPMD-B
  • OPMD-PM
  • OPMD
  • OPV
  • Tobacco
  • HPV
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants will be recruited into one of four cohorts, OSCC, OPC, OPMD, or cancer free cohorts.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed obtained
  • 18 years and older
  • At a high risk of developing oral or throat cancer based on clinician's discretion

Exclusion criteria

Exclusion Criteria

  • Pregnancy
  • Use of fertility enhancing medications
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
475 participants (estimated)
Patient registry
No

Groups and cohorts

  • Oral Squamous Cell Carcinoma (OSCC)

    OSCC case cohort will consist of patients with Oral Squamous Cell Carcinoma (all stages, locations), recruited from secondary care.

    Device: OralViome Cancer Testing System

  • OroPharyngeal Cancer (OPC)

    OPC case cohort will consist of patients with OroPharyngeal cancer (all stages, locations), recruited from secondary care.

    Device: OralViome Cancer Testing System

  • Oral Potentially Malignant Disease (OPMD)

    OPMD cohort will consist of patients with both potential malignancies or benign conditions including, but not limited to: * Dysplasia * Hyperplasia * Leukoplakia * Erythroplasia * Lichenoid lesions * Actinic Keratosis * Lichenoid reaction * Aphthous ulcer/ Canker Sores * Gingival enlargement (side effect) * Lichen planus * Keratosis * Inflammatory reaction * Cheek bites

    Device: OralViome Cancer Testing System

  • Cancer-free

    Cancer free control cohort will be matched with cases. Participants will be recruited following clinical adjudication with self-reported confirmation of no cancer and from primary care facilities.

    Device: OralViome Cancer Testing System

Interventions

  • DeviceOralViome Cancer Testing System

    The OralViome Cancer Testing System is intended for the screening of Oral Squamous Cell Carcinoma (OSCC) and Oropharyngeal cancer (OPC). The system consists of the OralViome Saliva Collection and Transport Kit, the Viome laboratory process for metatranscriptomics, and the Viome analytical software that detects an RNA expression signature within a saliva sample.

06

What researchers measure

Primary outcomes

  1. The primary endpoint will be the detection or not of OSCC or OPC

    The test results will be compared against the definitive diagnosis by the physician.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • NYMC
    New York, New York 10595, United States
    Recruiting
    • Mohanapriya Rajamoorthy · Contact(914) 594-4575
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2022 (actual). Primary completion is estimated for Dec 2026, 55 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2022
First posted
Jul 11, 2022
StartActual
May 27, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05451303
Lead sponsor
Viome
Collaborators
New York Medical College
Responsible party
Sponsor
First posted
Jul 11, 2022
Start date
May 27, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 29, 2025

Study contacts

Mory Mehrtash, MSc
Contact
studies@viome.com
425-300-6933
Momchilo Vuyisich, PhD
Contact
studies@viome.com
425-300-6933
Cristina Julian, PhD
principal investigator · Viome

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion